Janux Therapeutics (NASDAQ:JANX) VP Maria Dobek Sells 1,462 Shares

Janux Therapeutics, Inc. (NASDAQ:JANX) VP Maria Dobek sold 1,462 shares of Janux Therapeutics stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $13.73, for a total transaction of $20,073.26. Following the transaction, the vice president directly owned 15,373 shares in the company, valued at $211,071.29. This trade represents a 8.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Janux Therapeutics Stock Performance

JANX opened at $13.65 on Friday. Janux Therapeutics, Inc. has a one year low of $13.52 and a one year high of $61.59. The stock has a market capitalization of $821.05 million, a PE ratio of -8.13 and a beta of 2.88. The business’s 50 day moving average price is $22.51 and its 200 day moving average price is $23.74.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.21. The business had revenue of $10.00 million for the quarter, compared to analysts’ expectations of $3.07 million. As a group, equities research analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently commented on JANX shares. HC Wainwright lowered their price objective on shares of Janux Therapeutics from $70.00 to $45.00 and set a “buy” rating for the company in a research note on Tuesday, December 2nd. Barclays dropped their price objective on Janux Therapeutics from $48.00 to $29.00 and set an “overweight” rating on the stock in a report on Wednesday, December 17th. Wall Street Zen upgraded shares of Janux Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Truist Financial began coverage on Janux Therapeutics in a research report on Wednesday, September 10th. They set a “buy” rating and a $100.00 price target on the stock. Finally, Wolfe Research initiated coverage on shares of Janux Therapeutics in a report on Tuesday, November 18th. They issued a “peer perform” rating for the company. Twelve investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Janux Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $61.08.

More Janux Therapeutics News

Here are the key news stories impacting Janux Therapeutics this week:

• Negative Sentiment: CEO David Alan Campbell sold 8,072 shares (~$110,829); he still holds 284,982 shares. Form 4 – Campbell
• Negative Sentiment: Insider Thomas Diraimondo sold 2,505 shares (~$34,394); remaining position ~124,425 shares. Form 4 – Diraimondo
• Negative Sentiment: Zachariah McIver sold 2,714 shares (~$37,263); post-sale holding ~23,286 shares. Form 4 – McIver
• Negative Sentiment: VP Maria Dobek sold 1,462 shares (~$20,073); holds ~15,373 shares after the sale. Form 4 – Dobek
• Negative Sentiment: Insider Charles M. Winter sold 2,401 shares (~$32,966); remaining holding ~77,721 shares. Form 4 – Winter

Institutional Trading of Janux Therapeutics

A number of institutional investors have recently bought and sold shares of the company. Osaic Holdings Inc. boosted its position in shares of Janux Therapeutics by 704.6% in the 2nd quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock worth $80,000 after buying an additional 3,037 shares in the last quarter. Virtus Investment Advisers LLC grew its stake in Janux Therapeutics by 37.9% in the 2nd quarter. Virtus Investment Advisers LLC now owns 3,679 shares of the company’s stock worth $85,000 after acquiring an additional 1,011 shares during the period. Tower Research Capital LLC TRC grew its position in shares of Janux Therapeutics by 175.5% in the second quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock valued at $91,000 after purchasing an additional 2,502 shares during the period. Ameritas Investment Partners Inc. increased its stake in shares of Janux Therapeutics by 25.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,020 shares of the company’s stock valued at $93,000 after acquiring an additional 820 shares during the last quarter. Finally, Winthrop Capital Management LLC acquired a new position in Janux Therapeutics during the third quarter worth approximately $106,000. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.